Taro announces merger agreement with Sun Pharma

Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023

Piramal Pharma launches new concentration of Zinc Sulfate for Injection in U.S.

The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio

Lupin receives USFDA’s approval or Propranolol Hydrochloride Extended-Release Capsules USP

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US

Unichem receives ANDA approval for Doxazosin Tablets

Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US

Lupin receives USFDA approval for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Loteprednol Etabonate Ophthalmic Suspension, 0.2%, is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis

Natco Pharma and Breckenridge dismissed from antitrust lawsuit

Norms for fixing prices of medicines

NPPA fixes the ceiling price of scheduled formulations as per the extant provisions of DPCO, 201